CE vs ICL

Celanese Corporation exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health. Despite a recent 1-year price recovery, the company is struggling with negative profit margins (-12.21%), a deeply negative ROE (-22.52%), and a high Debt/Equity ratio of 2.89. Revenue and earnings are in sharp decline, with YoY EPS growth collapsing by 88.3%. The disconnect between the bearish deterministic health scores and the 'Buy' analyst consensus suggests a speculative outlook rather than a fundamental one.

ICL presents a precarious profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant valuation gap, with the current price ($5.54) trading well above both the Graham Number ($4.33) and the Intrinsic Value ($1.26). While the balance sheet is healthy with low debt (D/E 0.44), the company suffers from razor-thin profit margins (3.16%) and a highly unsustainable dividend payout ratio of 96.39%. Technicals are overwhelmingly bearish (0/100), and the stock has seen a 16.4% decline over the past year, suggesting a lack of market confidence despite a 'hold' analyst consensus.